---
document_datetime: 2026-01-06 09:17:26
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/spedra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: spedra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6912357
conversion_datetime: 2026-01-10 11:08:32.034008
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Spedra

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | This was an application for a group of | 05/01/2026                          |                                             | Annex II and                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000319544                     | variations. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted   |            | PL          |                                                                                                                                                  |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000236039 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.b Introduction of a manufacturer of the active substance supported by an ASMF - Accepted                                                                                                                          | 04/12/2025 |             |                                                                                                                                                  |
| Variation type II / EMA/VR/0000243987 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk                                                                                                                                                                                                                                                                                                                                                                                                                                          | 13/03/2025 | SmPC and PL | Update of the RMP (new version 6.0) in order to align withthe GVP Module V on Risk Management Systems and to update the list of safety concerns, |

<div style=\"page-break-after: always\"></div>

| management plan - C.I.11.b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment by the competent authority is required* - Accepted Submission of an updated RMP version 6.0 in order to align withthe GVP Module V on Risk Management Systems (EMA/838713/2011 Rev2*, 28 March 2017) and to update the list of safety concerns, according to the outcome of the latest two PSUSA procedures (EMEA/H/C/PSUSA/00010066/202006 and EMEA/H/C/PSUSA/00010066/202306). Update of the PI with inclusion of the adverse reaction of 'hypotension' in section 4.8 of the SmPC, with the PIL reflecting this accordingly.   | according to the outcome of the latest two PSUSA procedures (EMEA/H/C/PSUSA/00010066/202006 and EMEA/H/C/PSUSA/00010066/202306). Update of the PI with inclusion of the adverse reaction of 'hypotension' in section 4.8 of the SmPC, with the PIL reflecting this accordingly. For more information, please refer to the Summary of Product Characteristics.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|